Final approval is expected upon expiry of the product patent on December 29, 2007.
Upon final approval, Teva’s risperidone will be the AA-rated generic equivalent of Risperdal which is manufactured by Johnson & Johnsons Janssen LP.
Annual brand product sales in the US were approximately $66 million for the twelve months ended June 2006, according to Teva Pharmaceuticals.